Last $3.40 USD
Change Today +0.04 / 1.19%
Volume 6.2K
MNOV On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

medicinova inc (MNOV) Snapshot

Open
$3.32
Previous Close
$3.36
Day High
$3.42
Day Low
$3.31
52 Week High
01/14/14 - $5.25
52 Week Low
04/15/14 - $1.66
Market Cap
82.3M
Average Volume 10 Days
29.9K
EPS TTM
$-0.13
Shares Outstanding
24.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINOVA INC (MNOV)

Related News

No related news articles were found.

medicinova inc (MNOV) Related Businessweek News

No Related Businessweek News Found

medicinova inc (MNOV) Details

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a ß2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.

11 Employees
Last Reported Date: 03/27/14
Founded in 2000

medicinova inc (MNOV) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2013.

medicinova inc (MNOV) Key Developments

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders

MediciNova Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of certain liver disorders. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover a method of inhibiting steatosis, a method of inhibiting lobular inflammation, a method of inhibiting hepatic ballooning, a method of inhibiting hepatic scarring, and a method of reducing or inhibiting elevated liver hydroxyproline levels using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms. MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

MediciNova Inc. Wins Support from U.S. CDC's National ALS Registry Research Committee for Patient Recruitment of Clinical Trial MN-166

MediciNova Inc. announced that the U.S. CDC's National ALS Registry Research Committee has voted to approve support of patient recruitment for MediciNova's clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). CDC has notified ALS patients who are registered with the CDC's National ALS Registry and who also met the inclusion criteria about the initiation of MediciNova's clinical trial of MN-166 (ibudilast) in ALS. Subject enrollment in this trial began in early October 2014. The trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study will evaluate several efficacy endpoints including functional activity (ALSFRS-R), respiratory function, muscle strength, and non-invasive ventilation (NIV) utilization in addition to monitoring the safety and tolerability of MN-166 60 mg/day versus placebo when administered in combination with riluzole in subjects with ALS. The principal investigator of the study is Benjamin Rix Brooks, MD, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute in Charlotte, NC. Upon completion of the Double-blind Phase, subjects randomized to the placebo arm will continue for an additional 6 months and will receive open-label MN-166. If there are no safety or tolerability concerns in the MN-166 treated group, a decision will be made to extend participation to the MN-166 treated group into the Open-Label Extension (OLE) Phase. Otherwise, only the placebo-treated patients will participate in the OLE Phase. The primary objective is to evaluate the safety and tolerability of MN-166 60 mg/day versus placebo when administered for 6 months with riluzole in subjects with ALS. The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/day versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by the following assessments: Functional activity as assessed by the Amyotrophic Lateral Sclerosis; Functional Rating Scale-revised (ALSFRS-R); Respiratory function as measured by slow vital capacity (SVC), Maximum; Inspiratory Pressure (MIP) also known as Negative Inspiratory Force (NIF); and Forced Expiratory Volume in 1 second (FEV1) measured under SVC protocol; Muscle strength measured by manual muscle testing (MMT) and instrumented hand grip dynamometry; and non-invasive ventilation (NIV) utilization measured by clinically indicated prescription for NIV intervention and time to clinically indicated prescription for NIV intervention in each group.

MediciNova Announces U.S. Food and Drug Administration Granted Orphan Drug Designation to MN-001 (Tipelukast) for Idiopathic Pulmonary Fibrosis

MediciNova Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Orphan-drug designation will provide MediciNova with seven years of marketing exclusivity for MN-001 (tipelukast) for the treatment of IPF if it is approved for this indication.MediciNova previously opened an Investigational New Drug (IND) application with the Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) for MN-001 (tipelukast). MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNOV:US $3.40 USD +0.04

MNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNOV.
View Industry Companies
 

Industry Analysis

MNOV

Industry Average

Valuation MNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINOVA INC, please visit www.medicinova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.